Ground Swell Capital LLC Invests $27,000 in Applied Therapeutics, Inc. (NASDAQ:APLT)

Ground Swell Capital LLC purchased a new stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 31,636 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds have also bought and sold shares of APLT. Private Advisor Group LLC purchased a new position in shares of Applied Therapeutics during the fourth quarter valued at approximately $35,000. SG Americas Securities LLC raised its stake in Applied Therapeutics by 169.0% during the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after buying an additional 25,601 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Applied Therapeutics by 176.1% in the fourth quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock worth $45,000 after acquiring an additional 33,567 shares in the last quarter. Dark Forest Capital Management LP grew its stake in shares of Applied Therapeutics by 54.5% in the fourth quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company’s stock worth $46,000 after acquiring an additional 18,949 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of Applied Therapeutics during the fourth quarter valued at $49,000. Institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Price Performance

Shares of Applied Therapeutics stock opened at $0.40 on Friday. Applied Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $10.62. The firm’s 50-day moving average is $0.44 and its 200 day moving average is $2.24. The stock has a market cap of $56.59 million, a price-to-earnings ratio of -0.25 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.61 million. On average, equities analysts expect that Applied Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.